Based in the United States, Beam Therapeutics, Inc. is a pharmaceutical company specializing in genetic medicines utilizing base editing technology. With an ESG score of 26.1, it is considered a medium-risk investment. Beam Therapeutics focuses on Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. Their pipeline includes BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.